LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Northwestern University
University of Virginia
Genentech
Novartis
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier:
NCT00859222
First received: March 9, 2009
Last updated: January 3, 2014
Last verified: January 2014
  Purpose

The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has no yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.


Condition Intervention Phase
Malignant Glioma
Drug: LBH589
Drug: bevacizumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Resource links provided by NLM:


Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Phase I: To determine the maximum tolerated dose of LBH589 in combination with bevacizumab in this patient population. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Phase II: To determine the efficacy of LBH589 in combination with bevacizumab in this patient population as measured by 6-month progression-free survival. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Phase I: To define the safety of LBH589 and bevacizumab in this patient population. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Phase I: To characterize the pharmacokinetics of LBH589 in this population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Phase II: To determine the efficacy of LBH589 in combination with bevacizumab in this patient population by overall survival, time-to-tumor progression and objective tumor response. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Phase II: To further evaluate the safety profile of LBH589 and bevacizumab in this population. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Enrollment: 48
Study Start Date: March 2009
Estimated Study Completion Date: December 2014
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: LBH589
    Taken orally three times per week
    Drug: bevacizumab
    Given as an infusion intravenously on days 1 and 15 of each 28-day cycle
    Other Name: Avastin
Detailed Description:
  • Each treatment cycle lasts 28 days (four weeks). LBH589 is taken orally three times per week (i.e. Monday-Wednesday-Friday or Tuesday-Thursday-Sunday) every other week. Since we are looking for the highest dose of LBH589 that can be given safely to people who are also taking bevacizumab, not everyone who participates in this study will receive the same amount of the drug. The dose of LBH589 given will depend on the number of participants who have been enrolled and how well they tolerated their doses. The dose of bevacizumab will be the same for everyone.
  • On days 1 and 15 of each cycle, bevacizumab will be given as an infusion intravenously in the clinic.
  • The following tests and procedures will be performed at time intervals specified in the protocol: physical and neurological examination; assessments of the tumor by MRI or CT scan; routine blood tests; routine urine tests; pregnancy test for women of child bearing potential; research blood tests and an EKG.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written informed consent prior to participation in the study and any related procedures being performed.
  • Agreed to and signed an authorization for the release of their protected health information.
  • Must be 18 years of age or older
  • Karnofsky Performance Status 60 or greater
  • Life expectancy of at least 8 weeks
  • Histologic diagnosis of anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), or anaplastic mixed oligoastrocytoma (AMO) (Patients are eligible if the original histology was lower-grade glioma)

    ** NOTE: new accruals to patients diagnosed glioblastoma (GBM) / gliosarcoma have been placed on hold.**

  • Unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan. A scan must be performed within 14 days prior to registration and on a steroid dose that has been stable for at least 5 days. (Patients with recurrence who undergo resection and are left without measurable or evaluable disease are eligible.)
  • Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 60 days from the completion of radiation therapy to study entry.
  • Patients must have recovered from the toxic effects of prior therapy. Residual toxicity from any previous treatment must be Grade 1 or less.
  • Sufficient time for recovery from prior therapy: 28 days from any investigational agent, 28 days from prior cytotoxic therapy(except 23 days from prior temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine administration), and 7 days for non-cytotoxic agents.
  • Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon positron emission tomography (PET), Thallium scanning, MR spectroscopy or surgical documentation of disease.
  • Subjects who have undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply: a) prior to initiating therapy, 4 weeks must have elapsed since surgery (Subjects must have recovered from surgical-related trauma. Wound healing needs to have occurred.) b) residual disease following resection of recurrent malignant glioma is not mandated for eligibility. To assess the extent of residual disease postoperatively, a MRI or CT should be done at least 4 weeks postoperatively and within 14 days prior to registration.
  • Clinical laboratory tests within 14 days prior to enrollment meeting the criteria listed in the protocol
  • Cardiology assessment: Baseline MUGA or Echocardiogram must demonstrate LVEF 50% or greater
  • Electrocardiogram: A single screening ECG, taken within 14 days of registration, will be performed to assess study eligibility. Patients whose single QTc interval is ≤ 450 msec are eligible. Patients whose QTc interval is > 460 msec are ineligible. If the result is > 450 msec and ≤ 460 msec, two additional ECG readings are to be performed, each one separated by at least 5 minutes; in this case to be eligible, each individual QTc interval must be ≤ 460 msec and the average of the QTc intervals must be ≤ 450 msec.
  • Patient is non-hypertensive or has well-controlled hypertension (systolic blood pressure of < 140mm Hg or diastolic pressure < 90 mm Hg).
  • Female subjects of childbearing potential must have a negative pregnancy test confirmed both at screening and within 48 hours prior to dosing with the study drug
  • Female subjects of childbearing potential and male subjects with female partner of childbearing potential must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 3 months after stopping the medication.
  • Subjects must be free of any clinically relevant disease (other than glioma) that would, in the Investigator's opinion, interfere with the conduct of the study or study evaluations.
  • Subjects must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diary.

PHASE I Inclusion Criteria (the following modifications to the general eligibility criteria apply to Phase I patients only):

• Patients may have been treated for any number of prior relapses. Relapse is defined as progression following initial therapy

PHASE II Inclusion Criteria (phase II patients must meet the general eligibility criteria as well as the following):

  • Patients may have had treatment for no more than 2 prior relapses. (The intent therefore is that patients had no more than 3 prior therapies: initial and treatment for 2 relapses.)
  • It is mandatory that 15 unstained paraffin slides or 1 representative tissue block be available from original surgery or definitive surgery or the surgery closest to initiation of this clinical trial.

Exclusion Criteria:

  • Subject has received previous therapy with anti-VEGF targeted agents or with any histone deacetylase inhibitors. (Prior treatment with valproic acid for seizures is allowed but requires a washout of at least 14 days prior to starting LBH589.) Although concomitant use of the following drugs is not allowed on study, previous use is allowed, provided patients meet the following mandatory washout periods:

    i. Drugs w/ risk of causing TdP = 72 hrs; ii. Warfarin = 7 days.

  • History of grade 2 thrombocytopenia or grade 3 neutropenia on any prior regimen.
  • Presence of ≥ grade 2 peripheral neuropathy.
  • Bleeding diathesis or coagulopathy
  • History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician
  • Treatment with warfarin. (For patients requiring anticoagulation therapy, only therapeutic low molecular weight heparin or factor Xa inhibitors are permitted.)
  • Patients who have received any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
  • Patients with any disease that will obscure toxicity or dangerously alter drug metabolism
  • Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and has not received treatment for that particular disease for a minimum of 3 years
  • Impaired cardiac function as detailed in the protocol
  • Uncontrolled hypertension (systolic blood pressure >/= 140 mmHg and/or diastolic blood pressure >/= 90 mmHg) and/or prior history of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease within 6 months prior to Day 1
  • History of stroke or transient ischemic attack within 6 months prior to Day 1
  • Patients with unresolved diarrhea > CTCAE grade 1
  • Patients with INR > 1.5
  • Patients with major surgery or a significant traumatic injury within 28 days prior to Day 1
  • Patients with any condition that impairs their ability to swallow and/or absorb pills
  • Concomitant use of drugs with a risk of causing torsades de pointes
  • Concomitant use of CYP3A4 inhibitors during the treatment phase of the study and within 72 hours prior to starting treatment
  • Concomitant use of potent CYP3A4/5 inducers during the treatment phase of the study and within 2 weeks prior to starting treatment
  • Concomitant use of any anti-cancer therapy or radiation therapy, or any other investigational agent
  • Patients has known human immunodeficiency virus (HIV) of hepatitis C infection (baseline testing for HIV or hepatitis C is not required)
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to LBH589 or bevacizumab, or their excipients
  • Patient is in a situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study
  • Patient has a significant history of non-compliance to medical regimens
  • Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
  • History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
  • Serious, non-healing wound, active ulcer, or untreated bone fracture
  • Proteinuria as demonstrated by a UPC ratio of 1.0 or greater at screening
  • Subject is pregnant or intends to become pregnant during the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00859222

Locations
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Virginia
University of Virginia, Department of Neurology
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Patrick Y. Wen, MD
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Northwestern University
University of Virginia
Genentech
Novartis
Investigators
Principal Investigator: Patrick Y. Wen, MD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Patrick Y. Wen, MD, Director, Center For Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier: NCT00859222     History of Changes
Other Study ID Numbers: 08-342, CLBH589BUS42T
Study First Received: March 9, 2009
Last Updated: January 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Dana-Farber Cancer Institute:
LBH589
bevacizumab
Avastin

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 16, 2014